Pharmacogenomics study in a Taiwan methadone maintenance cohort
Sheng-Chang Wang1, Hsiao-Hui Tsou2, Ing-Kang Ho3
1Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan.
Journal of Food and Drug Analysis
|October 4, 2014
Summary
Genetic variants in key enzymes influence methadone treatment response. Single nucleotide polymorphisms (SNPs) in CYP genes affect methadone levels, withdrawal, side effects, and dosage, aiding personalized treatment strategies.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Methadone maintenance treatment is crucial for heroin dependence.
- Understanding genetic influences on methadone response can optimize therapy.
Purpose of the Study:
- To investigate the association between genetic variants and methadone treatment outcomes.
- To identify genetic markers for predicting methadone dosage, withdrawal symptoms, and side effects.
Main Methods:
- Genotyping of key metabolic (CYP2B6, CYP3A4, CYP2C19, UGT2B7) and pharmacodynamic (OPRM1) genes in 366 patients.
- Assessment of treatment outcomes using TOP, SDS, COWS, and TESS scales.
Main Results:
- SNPs in CYP2B6 correlated with S-methadone concentration.
- CYP3A4 SNPs were linked to withdrawal symptoms and side effects.
- CYP2C19 SNPs were associated with methadone dose.
- UGT2B7 SNPs related to withdrawal scores.
- OPRM1 SNPs correlated with insomnia and libido changes.
Conclusions:
- Genetic variations, particularly in CYP and OPRM1 genes, significantly impact methadone treatment.
- SNP markers show potential for personalized methadone dosage adjustment and adverse reaction reduction.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
01:27Pharmacogenetics of Drug Metabolism: Overview
184
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
184
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
01:29Therapeutic Drug Monitoring: Affecting Factors
420
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
420